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Abstract
Background: With evolving evidence of association between tuberculosis (TB) and tobacco smoking,
recommendations for the inclusion of tobacco cessation interventions in TB care are becoming increasingly
important and more widely disseminated. Connecting TB and tobacco cessation interventions has been strongly
advocated as this may yield better outcomes. However, no study has documented the impact of such connection
on health-related quality of life (HRQoL). The objective of this study was to document the impact of an integrated
TB directly observed therapy short-course (DOTS) plus smoking cessation intervention (SCI) on HRQoL.
Methods: This was a multi-centered non-randomized controlled study involving 120 TB patients who were current
smokers at the time of TB diagnosis in Malaysia. Patients were assigned to either of two groups: the usual TB-DOTS
plus SCI (SCIDOTS group) or the usual TB-DOTS only (DOTS group). The effect of the novel strategy on HRQoL was
measured using EQ-5D questionnaire. Two-way repeated measure ANOVA was used to examine the effects.
Results: When compared, participants who received the integrated intervention had a better HRQoL than those
who received the usual TB care. The SCIDOTS group had a significantly greater increase in EQ-5D utility score than
the DOTS group during 6 months follow-up (mean ± SD = 0.98 ± 0.08 vs. 0.91 ± 0.14, p = 0.006). Similarly, the
mean scores for EQ-VAS showed a consistently similar trend as the EQ-5D indices, with the scores increasing over
the course of TB treatment. Furthermore, for the EQ-VAS, there were significant main effects for group [F (1, 84) =
4.91, p = 0.029, h
2 = 0.06], time [F (2, 168) = 139.50, p = < 0.001, h
2 = 0.62] and group x time interaction [F (2, 168)
= 13.89, p = < 0.001, h
2 = 0.14].
Conclusions: This study supports the evidence that an integrated TB-tobacco treatment strategy could potentially
improve overall quality of life outcomes among TB patients who are smokers.
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Introduction
In recent years, there has been a global explosion of
interest in the association between tuberculosis (TB)
and tobacco smoking. Studies from different parts of the
world have sufficiently documented consistent evidence
that smoking substantially increases the risk of TB and
d e a t hf r o mi t[ 1 - 4 ] .T o b a cco smoking has in addition
found to be significantly correlated with poor TB treat-
ment outcomes and prognosis [5-8]. With such
emerging evidence of association between the two dis-
eases, recommendations for the inclusion of tobacco
cessation interventions in TB care are becoming increas-
ingly important and more widely disseminated [9-13].
Therefore, the integration of tobacco control with TB
control programs is an important global agenda of pub-
lic health significance. Patients undergoing TB treatment
under the directly observed therapy, short-course
(DOTS) are typically in regular contact with the health-
care provider for a minimum duration of six months. At
every encounter with their clients or patients, healthcare
providers in TB care settings have a unique opportunity
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expected that patients may be more amenable to health
education messages when they are ill and such periods
may be teachable moments for behavioral changes
[11,14,15]. Therefore, there are opportunities for
tobacco cessation interventions among TB patients that
are often grossly underutilized.
El Sony and colleagues have examined the feasibility
of introducing a brief tobacco cessation intervention for
new cases of pulmonary TB in Sudan [16]. The study
reported that healthcare providers had the willingness to
provide tobacco cessation counseling to TB patients and
that the intervention was feasible and effective for those
enrolled within routine TB service [16]. Following this
pioneering and landmark study by El Sony and associ-
ates, the International Union Against Tuberculosis and
Lung Disease (IUATLD) designed an educational series
on the provision of tobacco cessation interventions for
TB patients [14,15,17-21]. In this series, the authors
strongly advocated for the inclusion of brief smoking
cessation advice in standard TB case management
[14,15].
Other additional giant efforts along this direction have
been made by the IUATLD and the World Health Orga-
nization (WHO), leading to the development of two
comprehensive practice and policy guidelines on tobacco
cessation interventions in TB programs [22,23]. Cur-
rently, pilot projects are ongoing in a number of coun-
tries around the world. For instance, smoking cessation
service has been introduced in TB care management in
Rio de Janeiro, Brazil [24]. Similar services have also
been introduced through the Practical Approach to
Lung Health (PAL) at pilot sites in Indonesia, Nepal,
Kyrgyzstan, and Egypt [24]. What remains to be demon-
strated, however, are the impacts of such services on
treatment outcomes and health-related quality of life
(HRQoL).
HRQoL is increasingly been used as an outcome mea-
sure for assessing disease treatment and it is essential in
evaluation of new interventions or therapies [25]. In the
present study, we utilized the EuroQoL five-dimension
questionnaire (EQ-5D) to assess TB patients’ self-evalua-
tions of the impact of the disease and the associated
treatments on their physical, mental, and social well-
being and functioning. EQ-5D was selected because of
its track record of excellent psychometric properties and
it appeared to be a valid and reliable tool in TB setting.
Dion et al. have evaluated the feasibility and reliability
of EQ-5D among TB patients [26]. The instrument also
has the advantage of brevity and been linguistically vali-
dated in all the commonly spoken languages of the
country of study (Malay, Chinese, and Malaysian Eng-
lish). The primary aim of the current research was to
evaluate the impact of adding tobacco cessation
intervention to conventional DOTS for TB on clinical
and quality of life outcomes of patients undergoing
treatment for TB. Here, we report the potential impact
of the value added TB-tobacco treatment strategy on
HRQoL.
Materials and methods
Study design
A multi-centered prospective non-randomized con-
trolled trial using quasi-experimental design was con-
ducted in Malaysia. Using Transtheoretical Model
approach [27], 120 eligible participants who were cur-
rent smokers at the time of TB diagnosis were assigned
to either of two treatment groups: the usual TB-DOTS
plus SCI (SCIDOTS group) or the usual TB-DOTS
alone (DOTS group).
The study design can be schematically represented as
below:
In Figure 1 above, ~R signifies that there was no ran-
domization of subjects into the treatment groups. Yb
represents the baseline HRQoL outcome measures
(before the interventions were initiated), whereas Ya
implies the HRQoL outcomes at different periods during
the interventions. X1 and X2 represent the integrated
intervention and the usual TB care, respectively.
Study area and setting
This study was conducted at five chest clinics in Malay-
sia. The selected clinics were considered as TB referral
centers from which all diagnosis or confirmation of TB
cases must come from among the population they serve.
The research was reviewed and approved by the Medical
Research Ethics Committee of the National Institutes of
Health, Malaysia in April 2008.
Study sample and sample size determination
The sample for the present study included all current
cigarette smokers newly diagnosed with TB between
June 2008 and April 2009. Patients were referred at the
point of initiating DOTS regimen by attending physi-
cians to TB DOTS providers who were purposely
trained to provide tobacco cessation intervention in TB
care settings [13]. Patients were recruited into the study
upon fulfillment of eligibility criteria and written
Yb X1   Y a Â Intervention
x ~R------------------------------------------------------------
Yb  X 2  Y a Â Control
Figure 1 Study design for the integrated TB-tobacco
intervention study.
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requirements in this study were predicated on the pri-
mary outcome measure, that is the overall TB treatment
outcome based on comparison of TB cure rates between
the two treatment groups. A statistical power of 80% to
detect a moderate effect size (20% difference in cure
rates) at a 95% confidence level were applied in the
sample size determination. By WHO standard of care,
DOTS has a target to achieve a 95% cure rate in pre-
vious reports; therefore, we assumed a cure rate of 95%
and 75% in the intervention and the control groups,
respectively. The minimum sample size was estimated
as 48 per treatment arm with a 2-sided alpha level of
0.05. We assumed a dropout rate of 25%, giving rise to
60 participants to be recruited per each treatment arm.
Intervention
The participants in both the SCIDOTS and the DOTS
groups went to the clinics on daily-basis to receive TB
DOTS for at least 6 months. Eleven sessions of indivi-
dualized cognitive behavioral therapy (CBT) with or
without nicotine replacement therapy (NRT) were
offered to each participant in the SCIDOTS group,
while the DOTS group received the same number of
sessions of usual counseling for TB. The follow-up clinic
appointments for SCI (beginning on the quit date) were
as follows: weekly for the first month, fortnightly for the
second and third month, and monthly from the fourth
to the sixth month. HRQoL outcomes were measured
by using EQ-5D and the effects of the novel strategy on
these were determined by comparing the two groups.
A summary of the interventions provided and out-
comes measurements for each of the two treatment
groups is provided in Figure 2.
Study instrument and HRQoL outcome measures
The EQ-5D questionnaire was used for measuring the
q u a l i t yo fl i f eo ft h es t u d yp a r t i c i p a n t s .T h ei n s t r u m e n t
was subjected to standardized linguistic validation pro-
cesses for use in Malaysian population by EuroQoL
Group, UK. Permission was obtained prior to use in this
study. HRQoL outcomes were measured periodically (at
baseline, at 3 months, and at 6 months of TB treatment)
for all participants using the EQ-5D questionnaire,
which consists of two sections: the EQ-5D self-descrip-
tive assessment and the visual analogue scale (EQ-VAS)
[28-30]. The EQ-5D descriptive system comprises of five
domains (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression), each having three
response choices: no problems, moderate problems, and
severe problems. Participants were asked to indicate
their own health state by ticking in the box against the
most appropriate statement. Participants’ health state
classifications in the descriptive system were converted
into composite utility scores using the UK social tariff
[31,32]. In addition, patients also self-rated their health
by drawing a line to the EQ-VAS to represent their cur-
rent health status. EQ-VAS rates the current health sta-
tus from 0 to 100, where the endpoints are labeled as
best imaginable health state (100) and worst imaginable
health state (zero).
Statistical analyses
T h ed a t aw e r ea n a l y z e db yu s i n gS P S Sv e r s i o n1 6 . 0
(SPSS Inc., Chicago, IL) and the level of statistical signif-
icance was set ap r i o r iat p < 0.05. Homogeneity of
baseline data was determined by using two-sample tests
including Student’s t-test for normally distributed con-
tinuous variables, and Pearson’s chi-square (c
2)o rF i s h -
er’s exact test for categorical variables. In the analysis of
HRQoL, each domain of the EQ-5D self-descriptive
assessment was categorized into “no problem”, “moder-
ate problem”,a n d“severe problem” and the data were
presented as frequencies and percentages. c
2 or Fisher’s
exact tests were used to compare between the SCIDOTS
and the DOTS groups for each specific domain. The
EQ-5D health state classification for each subject was
converted into an overall utility score [31,32]. Means
and standard deviations for EQ-5D utility indices and
EQ-VAS scores were calculated and tabulated. Indepen-
dent t-test was employed to examine the effects of
group on HRQoL (measured using the EQ-5D utility
and EQ-VAS scores) from baseline to the end of the 6-
month follow-up. Furthermore, two-way repeated mea-
sure ANOVA was used to examine the main effect of
group (intervention and control), time (baseline, 3
months, and 6 months), and group x time interaction
on EQ-5D utility scores and EQ-VAS. Sphericity-
assumed estimates were applied if Mauchly’st e s ti n d i -
cated no violation of assumptions; otherwise, Green-
house-Geisser estimates were used.
Results
The similarity of the study groups with respect to
socio-demographic, disease- and smoking-related char-
acteristics was compared. This was done in order to
ascertain whether the groups were similar in related
characteristics, despite absence of randomization in the
design of the study. From the results obtained, subjects
in the two groups were homogenous with respect to
most of the characteristics [33]. Although participants
in the control group were older than those in the
intervention group (45.8 ± 14.4 years vs. 41.6 ± 14.4
years), this difference was not statistically significant (t
= -1.334, p = 0.186). The groups did not differ signifi-
cantly in relation to gender (Fisher’s Exact p =1 . 0 0 0 ) ,
ethnicity (Fisher’sE x a c tp = 0.431), and marital status
(Fisher’s Exact p = 0.961). In both groups, TB patients
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during diagnosis, the clinical presentations of TB dis-
ease were similar between the treatment groups.
Furthermore, the distribution of other baseline data
was not different between the intervention and the
control groups. Hence, the effect of the integrated TB-
tobacco intervention on HRQoL and other outcomes
was determined.
Tobacco cessation and TB treatment outcomes
Results related to tobacco cessation outcomes (i.e. quit-
ting smoking) were previously published elsewhere [33].
Abstinence was biochemically validated using exhaled
CO and saliva cotinine testing. The study recorded a
linear trend over time on 7-day point prevalence absti-
nence (PPA) and continuous abstinence (CA) in the
SCIDOTS group, whereas abstinence rates remained
Newly diagnosed TB Patients who smoke and volunteered to participate 
Control Group Intervention Group  
DOTS only 
[6-months anti-TB regimen]
--------------------------------------
First visit 
Â Received an overview of DOTS + TB counseling. 
Â Baseline KAB, tobacco use, smoking history and FTND 
were assessed. 
Â Encouraged to consider quitting smoking. 
TB treatment and follow-up visits 
Â Patients came on daily basis to receive DOTS. 
Â Patients referred to nearby treatment center if having 
difficulty returning to the clinic. 
Â Necessary follow-up visits as scheduled. 
Â Follow-up schedules for TB on 2-monthly basis: 2
nd, 4
th,
and 6
thmonth. 
Â Overall TB treatment outcome measured at 6 months. 
Â HRQoL measure at baseline, 3 months and 6 months. 
SCI follow-up visits during TB follow-up visits 
Â Conventional counseling on TB disease and medications 
compliance; but no behavioral counseling, educational 
materials, or smoking cessation medications were provided. 
Â Follow-up appointments for possible smoking cessation 
were done at 3 months and 6 months from the baseline. 
Â The above strategy is to rule-out/verify the possibility of 
quitting smoking even without the intervention. 
Â Validation of cessation via Breath CO monitoring using 
Micro – Smokerlyzer
®and cotinine dip-stick test (Saliva 
NikAlert®). 
DOTS + SCI 
[6-months anti-TB regimen + 6-month CBT± NRT]
-------------------------------------
First visit 
Â Received an overview of DOTS + SCI. 
Â Baseline KAB, tobacco use, smoking history and 
FTND were assessed. 
Â Establishment of target quit date. 
TB treatment and follow-up visits 
Â Patients came on daily basis to receive DOTS. 
Â Patients referred to nearby treatment center if having 
difficulty returning to the clinic. 
Â Necessary follow-up visits as scheduled. 
Â Follow-up schedules for TB on 2-monthly basis: 2
nd,
4
th, and 6
th month. 
Â Overall TB treatment outcome measured at 6 months. 
Â HRQoL measure at baseline, 3 months and 6 months. 
SCI follow-up visits and outcome measurements 
Â Individualized behavioral counseling, educational 
materials, and smoking cessation medications were 
provided. 
Â Selection of NRT products (nicotine gum, patch, 
inhaler) was based on cigarettes consumption/day, 
FTND and patient’s preferences. 
Â Patients were taught on appropriate use of the products 
and given a written guide. 
Â Duration of NRT was determined based on individual 
patient needs (at least 8 weeks). 
Â Follow-up appointments for SCI were weekly for the 
1
st  month, fortnightly for the 2
nd  and 3
rd month, and 
monthly from the 4
th  to 6
th  month. 
Â Validation of cessation via BreathCO using Micro – 
Smokerlyzer
®and cotinine dip-stick test (Saliva 
NikAlert®). 
Figure 2 Flowchart of the interventions used in the study (usual care vs. integrated intervention groups).
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sixth month of follow-up, patients who received the
integrated intervention had a significantly higher rate of
success in quitting smoking when compared with those
who received the usual TB care alone (78% vs. 9%,
respectively; p < 0.001). Further details on smoking ces-
sation and TB treatment outcomes could be found in
the study published by Awaisu et al. (2011).
The key findings in relation to HRQoL are broadly
classified under the two subheadings below.
EQ-5D self-descriptive assessment by dimension
Table 1 presents a comparison of self-description assess-
ment between the intervention and the control groups
in five domains. The Majority of the participants in
both groups reported no problems with mobility and
self-care for all time periods. The trends in changes
observed over time in these two dimensions were also
similar between the two treatment groups. Moreover,
there were no significant differences between partici-
pants in the SCIDOTS and the DOTS groups in their
self-rating of mobility and self-care at baseline, 3
months and 6 months (Table 1).
Conversely, substantial proportions of the TB patients
believed that they had moderate to severe problems in
relation to usual activities, pain/discomfort, and anxiety/
depression at diagnosis. At baseline, 12 patients (26.1%)
in the usual care group rated themselves as having mod-
erate problems with usual activities compared with 22
patients (55.0%) in the integrated intervention group (p
= 0.011). Interestingly, at six months, the proportion of
patients in the SCIDOTS group who had no problems
with this dimension was significantly higher than that of
patients in the DOTS group (95.0% vs. 76.1%; p =
0.015).
Furthermore, about two-thirds of the study partici-
p a n t si nb o t hg r o u p sa s s e s s e dt h e m s e l v e sa sh a v i n g
moderate to severe pain or discomfort during TB diag-
nosis (p = 0.234). This problem waned over time and at
the end of 6 months of treatment, all patients (100%) in
the integrated intervention group versus 87% in the
usual care group admitted that they experienced no pain
or discomfort (p = 0.028). A summary of these findings
is presented in Table 1. Similarly, during diagnosis,
about 52% of the TB patients in both arms considered
themselves as moderately anxious or depressed. Having
Table 1 Comparison of EQ-5D self-description assessment between control (DOTS) and intervention (SCIDOTS) groups
a
Dimension Assessment Baseline End of 3 months End of 6 months
DOTS (n =
46)
SCIDOTS (n =
40)
p-
value
DOTS (n =
46)
SCIDOTS (n =
40)
p-
value
DOTS (n =
46)
SCIDOTS (n =
40)
p-
value
No problem 32 (69.6%) 27 (67.5%) 43 (93.5%) 37 (92.5%) 43 (93.5%) 39 (97.5%)
MOBILITY Moderate
problem
13 (28.3%) 13 (32.5%) 0.603 3 (6.5%) 3 (7.5%) 1.000 3 (6.5%) 1 (2.5%) 0.620
Severe
problem
1 (2.2%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
No problem 34 (73.9%) 29 (72.5%) 43 (93.5%) 36 (90.0%) 44 (95.7%) 39 (97.5%)
SELF-CARE Moderate
problem
11 (23.9%) 11 (27.5%) 0.612 3 (6.5%) 4 (10.0%) 0.700 2 (4.3%) 1 (2.5%) 1.000
Severe
problem
1 (2.2%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
No problem 31 (67.4%) 18 (45.0%) 37 (80.4%) 34 (85.0%) 35 (76.1%) 38 (95.0%)
USUAL
ACTIVITIES
Moderate
problem
12 (26.1%) 22 (55.0%) 0.011 9 (19.6%) 5 (12.5% 0.395 11 (23.9%) 2 (5.0%) 0.015
b
Severe
problem
3 (6.5%) 0 (0) 0 (0) 1 (2.5%) 0 (0) 0 (0)
No problem 16 (34.8%) 13 (32.5%) 34 (73.9%) 33 (82.5%) 40 (87.0%) 40 (100.0%)
PAIN Moderate
problem
27 (58.7%) 27 (67.5%) 0.234 11 (23.9%) 7 (17.5%) 0.474 6 (13.0%) 0 (0) 0.028
Severe
problem
3 (6.5%) 0 (0) 1 (2.2%) 0 (0) 0 (0) 0 (0)
No problem 20 (43.5%) 17 (42.5%) 36 (78.3%) 35 (87.5%) 41 (89.1%) 38 (95.0%)
ANXIETY Moderate
problem
24 (52.2%) 21 (52.5%) 0.988 9 (19.6%) 4 (10.0%) 0.466 5 (10.9%) 2 (5.0%) 0.442
Severe
problem
2 (4.3%) 2 (5.0%) 1 (2.2%) 1 (2.5%) 0 (0) 0 (0)
aFisher’s Exact and
bChi-square (c
2) tests were applied in calculating p-values
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about two to four folds during each visit.
EQ-5D utility and EQ-VAS scores
The means and standard deviations for EQ-5D utility
indices and EQ-VAS scores were computed and sum-
marized in Table 2. There was no significant difference
at baseline between the SCIDOTS and the DOTS
groups for mean EQ-5D utility score (0.72 ± 0.20 vs.
0.70 ± 0.31, t = 0.37, p = 0.715). The integrated inter-
vention group had a greater, but statistically non-signifi-
cant increase in EQ-5D utility index when compared
with the usual care group at 3 months follow-up (mean
= 0.91 ± 0.16 vs. 0.87 ± 0.22, t = 0.98, p = 0.333). How-
ever, at 6 months follow-up, the former had significantly
greater increase in EQ-5D utility score than the latter
(mean = 0.98 ± 0.08 vs. 0.91 ± 0.14, t = 2.85, p = 0.006).
Similarly, the mean scores for EQ-VAS showed a closely
similar trend as the EQ-5D utility indices, with the
scores increasing over the course of TB treatment
(Table 2).
Two-way repeated measure ANOVA was used to
examine the main effect of group, time, and group x
time interaction on EQ-5D utility score and on EQ-VAS
score as shown in Table 3. Covariates were not used in
the analyses despite significant baseline differences
between the SCIDOTS and the DOTS groups in nico-
tine dependence [Fagerström test for nicotine depen-
dence (FTND) score] and in expired CO level, as there
was no significant correlation between the baseline
FTND score and the baseline EQ-5D utility index (r =
-0.11, p = 0.3); and between the baseline CO level and
baseline EQ-5D utility index (r = -0.21, p =0 . 0 6 ) .
Mauchly’s test of sphericity showed that the assumption
of sphericity was violated (c
2 =2 0 . 4 3 ,p < 0.001); thus,
Greenhouse-Geisser estimates were applied. There were
no significant main effects for group [F (1, 84) = 1.86, p
= 0.176, h
2 = 0.02] and group x time interaction [F (2,
138) = 0.548, p =0 . 5 4 5 ,h
2 = 0.006], but there was
significant main effect for time [F (2, 138) = 49.42, p <
0.001, h
2 = 0.37].
Similarly, the main effects of group, time, and group x
time interaction on EQ-VAS as shown in Table 3 were
assessed. Assumption of sphericity was met as indicated
by Mauchly’st e s to fs p h e r i c i t y( c
2 =2 . 5 ,p = 0.287);
thus, sphericity-assumed estimates were applied. There
were significant main effects for group [F (1, 84) = 4.91,
p = 0.029, h
2 = 0.06], time [F (2, 168) = 139.50, p <
0.001, h
2 = 0.62] and group x time interaction [F (2,
168) = 13.89, p <0 . 0 0 1 ,h
2 = 0.14]. In addition, more
in-depth analyses using pairwise comparison showed
significant mean differences across all levels: level 1 vs.
level 2 (Δmean = 16.03, p < 0.001); level 1 vs. level 3
(Δmean = 24.55, p < 0.001) and level 2 vs. level 3
(Δmean = 8.52, p < 0.001).
Discussion
This pilot project has demonstrated the potential advan-
tages of connecting tobacco dependence treatment with
TB treatment in improving quality of life outcomes. Our
findings suggest that the combination of DOTS for TB
and SCI via CBT and pharmacotherapy has a great
potential to yield better treatment outcomes among TB
patients who smoke [4,10,11,34]. The EQ-5D classifier
indicated that the usual activities, pain/discomfort, and
anxiety/depression domains seemed to be more affected
during diagnosis than other domains. Improvements in
all of the five dimensions of EQ-5D questionnaire were
however observed over time in both the integrated
intervention and the usual care groups. The participants
had shown improvements in both physical and mental
functioning. Moreover, no differences were observed
between the two groups in terms of mobility, self-care,
and anxiety/depression throughout the follow-up
periods.
During the last follow-up visit, however, significantly
greater proportions of participants enrolled in the SCI-
DOTS group rated themselves better from the perspec-
tive of usual activities and pain/discomfort when
Table 2 Health-related quality of life outcomes according to group assignment
a
HRQoL outcome measure Control Group (DOTS)n = 46 Intervention Group(SCIDOTS)n = 40 t (df = 84) p-value
b
EQ-5D utility index
Baseline 0.70 ± 0.31 0.72 ± 0.20 0.37 0.715
End of 3-months follow up 0.87 ± 0.22 0.91 ± 0.16 0.98 0.333
End of 6-months follow up 0.91 ± 0.14 0.98 ± 0.08 2.85 0.006
EQ-VAS
Baseline 57.04 ± 12.74 55.00 ± 13.83 -0.71 0.478
End of 3-months follow up 70.50 ± 13.62 73.60 ± 13.15 1.07 0.288
End of 6-months follow up 73.87 ± 12.01 87.28 ± 11.44 5.26 < 0.001
aPlus-minus values are means ± SD;
bp-values were calculated with the use of independent t-test for all continuous data reporting mean values
EQ-5D EuroQoL 5 dimensions; VAS visual analogue scale
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the context of this study may be rather subjective than a
real physical or bodily pain, as TB is not usually asso-
ciated with any physical injury or disability and the
majority of the participants did not have such abnormal-
ities. The improvements observed in pain/discomfort
domain could possibly be contributed by the corre-
sponding improvements in anxiety/depression.
In summary, the findings of the current study have
demonstrated the positive impacts of TB treatment,
especially when combined with SCI on self-descriptive
assessment of current health status. Previous studies
have documented that many aspects of TB along with
its treatment could potentially compromise patients’
HRQoL [35-37]. Clinical factors were observed to corre-
late with poorer HRQoL among TB patients. Some of
the factors reported to influence quality of life among
TB patients include disease duration, number of symp-
toms before treatment, reactivation of previous TB
infection, hemoptysis, hospitalization, underlying chronic
conditions, anemia, and baseline white blood cells
counts [38,39]. In the present study, most of the socio-
demographic and clinical characteristics were similar
between the two treatment groups at baseline; therefore,
it is unlikely that the differences observed in HRQoL
were due to variations in these variables.
Likewise, the HRQoL of TB smokers measured using
both EQ-5D utility scores and EQ-VAS was relatively
low at baseline (before initiation of treatment), signifying
a decline in HRQoL [36,37,39]. We believe that the
decline seen in the qualityo fl i f eo fT Bs m o k e r sm a y
probably be multidimensional and contributed by other
factors as discussed previously. Consistent with the 5-
item descriptive system, the EQ-VAS score and the EQ-
5D utility index both increased consistently over time,
suggesting that patients generally continued to improve
over time during TB treatment. These observations
strongly support previous studies of increased quality of
life for patients receiving TB treatment [37,38,40].
The a priori assumption that participants in the inte-
grated intervention arm would have greater increases in
HRQoL during 3 months and 6 months follow-up
assessments was tested using two-way repeated measure
ANOVA. Over the TB treatment period, higher EQ-5D
utility score gains and EQ-VAS score gains were
observed among patients who received the SCIDOTS
intervention compared to those who received DOTS
only, especially at 6 months. Overall, the anti-TB treat-
ment, especially when combined with tobacco cessation
appeared to have a positive and greater impact on
improving patients’ HRQoL. Moreover, the physical
health of the participants tended to recover more
quickly than their mental well-being. Despite heteroge-
neity in measuring instruments, these findings are con-
sistent with other quality of life studies in TB setting
[38,40]. However, the findings should be interpreted
with the notion that ceiling and floor effects are a com-
mon problem for the application of health utility instru-
ments in TB [35].
It is also worthwhile to highlight nicotine withdrawal
syndrome as an important confounder in the anxiety/
depression domain of the EQ-5D. Participants who
received the SCI tended to present with nicotine with-
drawal symptoms including anxiety and depression
[41,42]. This may invariably have an overall net effect
on the quality of life. This implies that the quality of life
of the intervention group could have even been better
than it were.
The major strength of the current study is the applica-
tion of an intensive tobacco cessation intervention; using
a combination of pharmacotherapy and CBT rather than
brief intervention in the evaluation of the impact of an
Table 3 Two-way repeated measure ANOVA summary for EQ-5D utility index and EQ-VAS
EQ-5D utility index
Source Type III sum of squares Df Mean square F p-value* Partial Eta squared
Group .128 1 .128 1.864 .176 .022
Error (between subjects) 5.789 84 .069
Time (trial) for EQ-5D utility score 2.592 1.642 1.579 49.421 .000 .370
Group*Time .029 1.642 .018 .548 .545 .006
Error (within subjects) 4.406 138 .026
EQ-VAS
Source Type III sum of squares Df Mean square F p-value* Partial Eta squared
Group 1491.599 1 1491.599 4.906 .029 .055
Error (between subjects) 25538.509 84 304.030
Time (trial) for EQ-VAS 26594.807 2 13297.404 139.50 .000 .624
Group*Time 2648.218 2 1324.109 13.891 .000 .142
Error (within subjects) 16013.696 168 95.320
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ting on treatment outcomes and quality of life. The
study has also utilized biochemical measures rather than
self-reporting alone in the validation of smoking absti-
nence. Moreover, it has expanded its scope to investi-
gate humanistic outcomes, particularly HRQoL.
Nevertheless, there were some limitations to the study.
Most notably, the study used a non-randomized con-
trolled design. The non-randomized approach to group
assignment was in the light of the nature of nicotine
addiction, which necessitated us to adopt the Trans-
theoretical Model of Stages of Change during the
assignment of subjects into the treatment groups. Con-
sequently, there were inherent potential threats to inter-
nal validity such as selection bias, because assignment to
groups was based on individual participant’s decision.
Conclusion
The present study has demonstrated a potential positive
impact of connecting smoking cessation to DOTS, with
documented effects on overall HRQoL of TB patients
who smoke. The findings suggest that the integrated
approach may confer advantages on HRQoL on short-
a n dl o n g - t e r m .T h el e s s o n sl e a r n tf r o mt h i sp i l o ts t u d y
can be applied to expansion and scale-up projects in the
future. Future studies should evaluate the long-term
benefits of the integrated TB-tobacco intervention
approach on several outcomes of interest.
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